This review elucidates the dual mechanism of action of PD-1/PD-L1 inhibitors in this patient population: on one hand, blockade of the PD-1/PD-L1 axis enhances anti-tumor activity <i>in vivo</i>, while on the other, it reverses latent HIV infection and restores immune function. Here, CD274 is linked to neoplasm.